Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 47

1.

[A new therapeutic scene in the treatment of the chronic hepatitis for virus C].

Morillo Verdugo R, Romero Gómez M.

Farm Hosp. 2012 Nov-Dec;36(6):466-8. doi: 10.7399/FH.2012.36.6.56. Spanish.

2.
3.

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.

Swiss Association for the Study of the Liver.

Swiss Med Wkly. 2012 Feb 24;142:w13516. doi: 10.4414/smw.2012.13516. Review.

4.

A practical guide for the use of boceprevir and telaprevir for the treatment of hepatitis C.

Jacobson IM, Pawlotsky JM, Afdhal NH, Dusheiko GM, Forns X, Jensen DM, Poordad F, Schulz J.

J Viral Hepat. 2012 May;19 Suppl 2:1-26. doi: 10.1111/j.1365-2893.2012.01590.x. Review.

PMID:
22404758
5.

Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C.

Cammà C, Petta S, Cabibbo G, Ruggeri M, Enea M, Bruno R, Capursi V, Gasbarrini A, Alberti A, Craxì A; WEF Study Group.

J Hepatol. 2013 Oct;59(4):658-66. doi: 10.1016/j.jhep.2013.05.019. Epub 2013 May 23.

PMID:
23707373
6.

Economics of chronic hepatitis B and hepatitis C.

Rajendra A, Wong JB.

J Hepatol. 2007 Oct;47(4):608-17. Epub 2007 Jul 30. Review.

PMID:
17697724
7.

How to optimize HCV therapy in genotype 1 patients: predictors of response.

Petta S, Craxì A.

Liver Int. 2013 Feb;33 Suppl 1:23-9. doi: 10.1111/liv.12053. Review.

PMID:
23286842
8.

A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.

Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, Lee WM.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):1014-20.e1-2. doi: 10.1016/j.cgh.2013.03.032. Epub 2013 Apr 16.

PMID:
23602817
9.

Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C.

Gellad ZF, Reed SD, Muir AJ.

Antivir Ther. 2012;17(6 Pt B):1189-99. doi: 10.3851/IMP2430. Epub 2012 Oct 5. Review.

PMID:
23186646
10.

Telaprevir: a hepatitis C NS3/4A protease inhibitor.

Matthews SJ, Lancaster JW.

Clin Ther. 2012 Sep;34(9):1857-82. doi: 10.1016/j.clinthera.2012.07.011. Epub 2012 Aug 28. Review.

PMID:
22951253
11.

[Economic evaluation of combined therapy in chronic hepatitis C].

Casado MA, Buti M, Fosbrook L, Esteban R.

Gastroenterol Hepatol. 2000 Feb;23 Suppl 1:57-62. Review. Spanish. No abstract available.

PMID:
11968346
12.

[Quality of care and health economics in occupationally acquired hepatitis C in German health care workers between 1993 and 2004].

Reiser M, Haverkamp A, Dintsios M, Mölleken C, Krauth C, Pieper W, Schmiegel W.

Dtsch Med Wochenschr. 2007 Aug;132(34-35):1743-7. German.

PMID:
17713882
13.

[Chronic hepatitis C].

Grammatikos G, Sarrazin C.

Dtsch Med Wochenschr. 2010 Dec;135(50):2525-34; quiz 2535-8. doi: 10.1055/s-0030-1269423. Epub 2010 Dec 7. Review. German.

PMID:
21140330
14.

[Antiviral treatment of chronic hepatitis C].

Berger A.

Med Monatsschr Pharm. 2012 Feb;35(2):55-60. Review. German.

PMID:
22400430
15.

[Expert opinion on boceprevir- and telaprevir-based triple therapies of chronic hepatitis C].

Sarrazin C, Berg T, Cornberg M, Dollinger M, Ferenci P, Hinrichsen H, Klinker H, Kraus M, Manns M, Mauss S, Peck-Radosavljevic M, Schmidt H, Spengler U, Wedemeyer H, Wirth S, Zeuzem S.

Z Gastroenterol. 2012 Jan;50(1):57-72. doi: 10.1055/s-0031-1282015. Epub 2012 Jan 5. Review. German.

PMID:
22222799
16.

Current standards in the treatment of chronic hepatitis C.

Hofmann WP, Sarrazin C, Zeuzem S.

Dtsch Arztebl Int. 2012 May;109(19):352-8. doi: 10.3238/arztebl.2012.0352. Epub 2012 May 11.

17.

Antiviral activity of the new DAAs for the treatment of hepatitis C virus infection: virology and resistance.

Chevaliez S.

Clin Res Hepatol Gastroenterol. 2011 Dec;35 Suppl 2:S46-51. doi: 10.1016/S2210-7401(11)70007-9.

PMID:
22248694
18.

Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.

Cammà C, Petta S, Enea M, Bruno R, Bronte F, Capursi V, Cicchetti A, Colombo GL, Di Marco V, Gasbarrini A, Craxì A; WEF Study Group.

Hepatology. 2012 Sep;56(3):850-60. doi: 10.1002/hep.25734. Epub 2012 Jul 12.

PMID:
22454336
19.

Hepatitis C virus treatment and liver transplantation in the era of new antiviral therapies.

Saxena V, Terrault N.

Curr Opin Organ Transplant. 2012 Jun;17(3):216-24. doi: 10.1097/MOT.0b013e3283534d64. Review.

PMID:
22476221
20.

Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis.

Cure S, Diels J, Gavart S, Bianic F, Jones E.

Curr Med Res Opin. 2012 Nov;28(11):1841-56. doi: 10.1185/03007995.2012.734798. Epub 2012 Oct 31.

PMID:
23016967

Supplemental Content

Support Center